

Molecular Dissection of Benzodiazepine Binding and Allosteric Coupling Using Chimeric γ -Aminobutyric Acid_A Receptor Subunits

ANDREW J. BOILEAU, AMY M. KUCKEN, AMY R. EVERS, and CYNTHIA CZAJKOWSKI

Department of Neurophysiology, University of Wisconsin-Madison, Madison, Wisconsin 53706

Received September 2, 1997; Accepted October 24, 1997

This paper is available online at <http://www.molpharm.org>

ABSTRACT

Although γ -aminobutyric acid (GABA)_A receptor α subunits are important for benzodiazepine (BZD) binding and GABA-current potentiation by BZDs, the presence of a γ subunit is required for high affinity BZD effects. To determine which regions unique to the γ 2S subunit confer BZD binding and potentiation, we generated chimeric protein combinations of rat γ 2S and α 1 subunits using a modified protocol to target crossover events to the amino-terminal extracellular region of the subunits. Several chimeras with full open reading frames were constructed and placed into vectors for either voltage-clamp experiments in *Xenopus laevis* oocytes or radioligand binding experiments in human embryonic kidney 293 cells. Chimeras (χ) containing at least the amino-terminal 161 amino acids of γ 2S bound BZDs

with wild-type affinity when coexpressed with α 1 and β 2 subunits. Further analysis of the γ 2S binding site region uncovered two areas, γ 2S K41-W82 and γ 2S R114-D161, that together are necessary and sufficient for high affinity BZD binding. Surprisingly, although the 161-amino acid residue amino terminus of the γ 2S subunit is sufficient for high affinity BZD binding, it is not sufficient for efficient allosteric coupling of the GABA and BZD binding sites, as demonstrated by reduced diazepam potentiation of the GABA-gated current and GABA potentiation of [³H]flunitrazepam binding. Thus, by using γ/α chimeras, we identified two γ 2 subunit regions required for BZD binding that are distinct from domain or domains responsible for allosteric coupling of the BZD and GABA binding sites.

GABA_A receptors are the major inhibitory neurotransmitter receptors in the mammalian brain and are members of a ligand-gated ion channel superfamily (Ortells and Lunt, 1995), which includes receptors for acetylcholine, glycine, and serotonin. Molecular cloning studies have identified several different classes and isoforms of GABA_A receptor subunits, including 6 α , 4 β , 3 γ , 1 δ , and 2 ρ subunit subtypes (Sieghart, 1995). The majority of the GABA_A receptors in the brain are likely to consist of α 1, β 2, and γ 2 subunits (Stephenson, 1995). These receptors are pentameric proteins containing an integral chloride-selective channel with specific binding sites for GABA, BZDs, barbiturates, steroids, and picrotoxin (Sieghart, 1995; Smith and Olsen, 1995). BZDs, clinically used for their anxiolytic, muscle-relaxant, sedative, and antiepileptic actions, exert their therapeutic effects by allosterically modulating the activation of the GABA_A recep-

tor. Because of their clinical usefulness, a substantial effort has been made to understand the structural determinants within the receptor that underlie BZD binding and allosteric coupling.

Evidence suggests that both the α and γ subunits play critical roles in BZD binding and potentiation. By analogy to the agonist binding site of the nicotinic acetylcholine receptor (Karlin and Akabas, 1995), the BZD binding site of the GABA_A receptor has been modeled with a γ subunit apposed to an α subunit, with adjacent faces of the subunits contributing to the binding site (Smith and Olsen, 1995). Alternatively, any subunit may bind BZD itself but have this ability enhanced by conformational changes conferred by the presence of the γ subunit, which is required for high affinity BZD effects (Pritchett *et al.*, 1989). Regardless, understanding the roles of the α and γ subunits in BZD binding and modulation requires discovery of the specific structural elements involved.

In the α 1 subunit, several amino acid residues have been identified that are important for BZD effects. Photoaffinity-labeling (Smith and Olsen, 1995; Duncalfe *et al.*, 1996) and mutagenesis experiments (Wieland *et al.*, 1992; Kleingoor *et al.*, 1993) have identified histidine at position 101 (H101) as

This work was supported in part by a grant to the University of Wisconsin Medical School under the Howard Hughes Medical Institute Research Program for Medical Schools and by grants to C.C. from The Epilepsy Foundation of America, National Institutes of Health—National Institute of Neurological Disorders and Stroke, and the March of Dimes Birth Defects Foundation. C.C. is a recipient of the Burroughs Wellcome Fund New Investigator Award in the Basic Pharmacological Sciences. Portions of this work have been reported previously in abstract form (Boileau *et al.*, 1996).

ABBREVIATIONS: BZD, benzodiazepine; GABA, γ -aminobutyric acid; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HEK, human embryonic kidney; TRCP, targeted random chimera production.

forming part of the BZD binding site. Experiments using $\alpha 1/\alpha 3$ chimeras point to $\alpha 1$ G200 as another potential site for BZD effects (Pritchett and Seeburg, 1991). Other residues in $\alpha 1$ implicated in BZD binding include T162 and V211 (Wieland and Luddens, 1994), Y161 and T206 (Buhr et al., 1996), and Y159 and Y209 (Amin et al., 1997). Taken together, these results suggest that three separate domains of the $\alpha 1$ subunit, near H101, Y159-T162, and G200-V211, are involved in BZD binding.

Less evidence has been gathered regarding the BZD-responsive regions of the γ subunit. Mutagenesis experiments have identified two amino acids (F77 and T142) in the $\gamma 2$ subunit that may play a role in BZD effects. Mutation of Thr142 to serine ($\gamma 2$ T142S) altered the efficacy of several BZD ligands; both an antagonist (Ro15-1788) and a weak inverse agonist (Ro15-4513) took on the character of partial agonists (Mihic et al., 1994). Mutation of Phe77 to leucine ($\gamma 2$ F77L) enhanced diazepam potentiation of the GABA-mediated Cl^- current (Buhr et al., 1996), even though the binding affinity of diazepam was reduced. Substitution of $\gamma 2$ F77 with other amino acids had complex effects on BZD pharmacology (Buhr et al., 1997).

Both $\gamma 2$ F77 and $\gamma 2$ T142 are conserved in the aligned sequence of $\alpha 1$. The α subunit, even though it contains the homologous phenylalanine and threonine residues, cannot substitute for a γ subunit in conferring BZD effects. $\alpha\beta$ receptors do not bind BZDs or exhibit BZD-induced potentiation of the GABA-activated Cl^- current, whereas $\alpha\beta\gamma$ receptors do. Thus, other residues specific to the γ subunit are required for BZD binding and modulation.

To determine which regions unique to the $\gamma 2$ S subunit confer BZD binding and potentiation, we generated chimeric protein combinations of rat $\gamma 2$ S and $\alpha 1$ subunits. Chimeric

studies have the potential to target whole domains, which is important if we envision the drug binding site as a pocket formed by the side chains of a variety of amino acids from one or more regions of a subunit. Using this method, we identified two domains of $\gamma 2$ S that are, in conjunction, necessary and sufficient for high affinity BZD binding. In addition, we demonstrated that the $\gamma 2$ S regions responsible for high affinity BZD binding are distinct from the $\gamma 2$ S regions necessary for efficient allosteric coupling of the BZD binding site to the GABA binding site. The construction of chimeric subunits that exhibit wild-type binding but reduced allosteric coupling of GABA and BZD binding sites affords new probes for elucidating the structural components of allosteric modulation.

Materials and Methods

Molecular cloning. Chimeras (χ) were generated by placing the rat $\gamma 2$ coding region 5' to and in register with the rat $\alpha 1$ sequence in pBlueScript SK⁻ (Stratagene, La Jolla, CA). The dual plasmid (pTRCP, Fig. 1A) was digested, and the linearized plasmid was recircularized in bacteria by random homologous crossover events (Moore and Blakely, 1994). To create chimeric subunits containing amino-terminal domains of the $\gamma 2$ S subunit and carboxyl-terminal domains of the $\alpha 1$ subunit, we cut the dual-subunit plasmid with a restriction enzyme that cuts only in each coding region of $\gamma 2$ S and $\alpha 1$ (either *Afl*II or *Bbs*I). A fragment consisting mostly of the transmembrane and 3' coding regions of $\gamma 2$ S was released. The remaining linearized plasmid contained $\gamma 2$ S and $\alpha 1$ sequences with restricted regions of homology. Because appropriate crossovers can occur only in a small area delimited by the chosen restriction enzyme or enzymes, we named this method TRCP. Using this method, dozens of chimeric subunits with crossovers in the 5' (extracellular) region were generated in XL1-Blue cells, an *endA*⁻ strain that facilitates plasmid miniprep production. The chimeric open reading frames were subcloned into pGH19 (Liman et al., 1992; Robertson et al.,




Fig. 1. TRCP. A, Chimeras were generated by placing the $\gamma 2$ S coding region (2.0 kb) 5' to and in register with the $\alpha 1$ sequence (1.65 kb) in pBlueScript SK⁻ (2.9 kb; Stratagene) to yield pTRCP (6.55 kb). When linearized and introduced into competent coliform cells, the plasmid was recircularized by crossover events in homologous regions within the plasmid construct (see Materials and Methods). By choosing restriction enzymes that cut both $\gamma 2$ S and $\alpha 1$ (e.g., *Afl*II), the transmembrane and 3' coding region of $\gamma 2$ was released, and sufficient $\alpha 1$ and $\gamma 2$ 5' sequence was left to allow for crossover events. Black, $\gamma 2$ S sequence. White, $\alpha 1$ sequence. Gray, crossover areas made available by digestion with *Afl*II. B, TRCP chimeras were screened from four independent trials and contained 5' $\gamma 2$ S and 3' $\alpha 1$ sequence, the amount of which was determined by restriction digest mapping and DNA sequencing. The chimeras (χ) generated by TRCP are named for the amino acid of where the crossover transitions occurs and fell into six major groups ($\chi 40$, $\chi 82$, $\chi 107$, $\chi 113$, $\chi 161$, and $\chi 167$). Three additional non-TRCP chimeras were made (see Materials and Methods) and are named for the $\gamma 2$ S segments each contains. For example, $\chi 40/114-161$ contains $\gamma 2$ S sequence from Q1 to N40 and from R114 to D161. $\chi 114-161$ contains only $\gamma 2$ S sequence from R114 to D161. Black, $\gamma 2$ S sequence. White, $\alpha 1$ sequence. Gray, transmembrane segments M1 through M4.

1996) for expression in oocytes or into pCEP4 (InVitrogen, San Diego, CA) for transient expression in HEK 293 cells. For the TRCP chimeras generated in this study (Fig. 1B), the γ 2S and α 1 amino acids at which the crossovers occur are γ N40/ α R28 (χ 40), γ W82/ α K70 (χ 82), γ W107/ α T95 (χ 107), γ F113/ α H101 (χ 113), γ D161/ α A149 (χ 161), and γ L167/ α K155 (χ 167). Chimeras χ 40, χ 82, χ 107, and χ 113 were generated by *A*/II digestion, whereas χ 161 and χ 167 used *B*bsI digestion.

Chimera χ 114–161 (Fig. 1B) was produced by recombinant polymerase chain reaction using an oligonucleotide (5'-CCAGTA-AAATCTGGACTCCAGACACTTTCCTCAGGAAGTCC-3') designed to create an α F100/ γ R114 crossover. Using this 5' oligonucleotide and a downstream complementary α 1 oligonucleotide (5'-CTGG-GAGAGAATGACTGTC-3') with chimera χ 161 as template, a 456-base pair polymerase chain reaction fragment with α 1 5' and 3' flanks and γ 2 114–161 sequence was generated and subcloned into wild-type α 1 cDNA using *Bal*I and *Nsi*I. The resulting chimera contained α 1 sequence except in the region from H101 to D148. This region contained the homologous γ 2 region (R114 to D161). Chimeras χ 40/114–161 and χ 82/114–161 (Fig. 1B) were produced by digesting χ 114–161 with *Msc*I and *Nde*I, which flank the γ 2 114–161 sequence, and subcloning the resultant 749-base pair fragment into χ 40 and χ 82. The resulting chimeras replaced the α 1 region from H101 to D148 in both χ 40 and χ 82 with the homologous γ 2S region (R114–D161). All chimeras were verified by restriction digest and double-stranded DNA sequencing using standard techniques (Sambrook *et al.*, 1989).

Transient expression in HEK 293 cells. Rat α 1, β 2, γ 2S, and chimeric subunit cDNAs were subcloned into the multiple cloning site of a mammalian expression vector (pCEP4; InVitrogen) for transient transfection of HEK 293 cells (American Type Culture Collection CRL 1573). Cells were grown onto 100-mm tissue culture dishes in minimum essential medium with Earle's salts (Life Technologies, Grand Island, NY) containing 10% fetal bovine serum (Hyclone Laboratories, New Brunswick, NJ) in a 37° incubator under a 5% CO₂ atmosphere. Cells were cotransfected at 40–50% confluency with pCEP- α 1, pCEP- β 2, pCEP- γ 2, and/or pCEP- χ using a standard CaHPO₄ method (Graham and Eb, 1973). In general, cells were transfected with equal ratios of subunit DNA (5 μ g/subunit). Cells were harvested and membrane homogenates prepared 48–72 hr after transfection.

Binding assays. Cells were scraped from the dishes and pelleted by centrifugation (1000 \times *g*, 10 min, 4°). The cells were washed once and resuspended in a HEPES buffer containing 124 mM NaCl, 2.9 mM KCl, 1.3 mM MgSO₄, 1.2 mM KH₂PO₄, 25.0 mM HEPES, 5.2 mM D-glucose, and 2 mM EDTA; pH 7.4 and homogenized using a Polytron homogenizer (Brinkmann Instruments, Westbury, NY). The homogenates were centrifuged (30,000 \times *g*, 20 min, 4°), and the resulting pellets were resuspended in HEPES buffer. Protein concentrations were determined using a Bradford assay (BioRad, Hercules, CA) with bovine serum albumin as a standard.

For BZD saturation binding experiments, membrane homogenates (100 μ g) were incubated at room temperature with seven to nine concentrations of [³H]flunitrazepam (86 Ci/mmol; DuPont-New England Nuclear, Boston, MA) in the absence and presence of 20 μ M diazepam or 100 μ M flurazepam to determine total and nonspecific binding, respectively (final volume, 250 μ l). The unlabeled BZDs, flunitrazepam, diazepam, Ro15–1788, and Ro15–4513 were generously supplied to us by Dr. Sepinwall (Hoffman-La Roche, Nutley, NJ). Flurazepam was obtained from Research Biochemicals (Natick, MA). [³H]Muscimol (15.7 Ci/mmol; DuPont-New England Nuclear) binding experiments were performed similarly; 1 mM GABA or 100 μ M muscimol was used to determine nonspecific binding. All points were determined in triplicate. After reaching equilibrium, the incubations were vacuum filtered through glass-fiber filters (Reeves Angels; Whatman, Clifton, NJ) using a cell harvester (model MB-48; Brandel, Montreal, Quebec, Canada) and washed with eight times with 0.25 ml of HEPES buffer. Specific binding was defined as the

amount of tritium bound in the absence of displacing ligand minus the amount bound in the presence of displacer. Nonspecific binding was ~20–30% of total binding at *K_D* concentrations of radioligand. In general, *K_D* and *B_{max}* were determined by fitting specific binding data to a single site using the equation $y = B_{\max} * x / (K_D + x)$, where *y* is specifically bound dpm, and *x* is the radiolabeled drug concentration (Prism; GraphPAD Softward, San Diego, CA).

Competition experiments with various BZD-site ligands were done under the same general conditions, except seven to nine concentrations of nonradioactive competing ligand were used to displace specifically bound radioligand. Data were fit by using a nonlinear least-squares method to the equation $y = B_{\max} / [1 + (x/IC_{50})]$, where *y* is the specifically bound dpm, *B_{max}* is maximal binding, and *x* is the concentration of displacing drug (Prism). *K_I* was calculated according to the Cheng-Prusoff/Chou equation (Cheng and Prusoff, 1973; Chou, 1974).

To measure GABA potentiation of [³H]flunitrazepam binding (Czajkowski *et al.*, 1989), membrane homogenates were incubated for 60 min at room temperature with 3–5 nM [³H]flunitrazepam in the presence of six different concentrations of GABA (ranging from 100 nM to 10 μ M) and then filtered as described. The potentiation was calculated for each GABA concentration as follows: $p = (\text{dpm}_{\text{GABA}} / \text{dpm}_{\text{control}}) - 1$, where dpm_{GABA} is the specific [³H]flunitrazepam bound in the presence of GABA, and $\text{dpm}_{\text{control}}$ is the specific [³H]flunitrazepam bound in the absence of GABA.

Expression in oocytes. Capped cRNA coding for the wild-type and chimeric subunits was synthesized by *in vitro* transcription from *Nhe*I-linearized cDNA template using the mMessage mMachine T7 kit (Ambion, Austin, TX). Oocytes from *Xenopus laevis* were prepared by incubating small pieces of ovary in collagenase (2 mg/ml) in ND96/Ca²⁺-free media containing 96 mM NaCl, 2 mM KCl, 1 mM MgCl₂, and 5 mM HEPES, pH 7.6, for 40 min at room temperature. The digested ovaries were washed several times in ND96, followed by several washes in recording solution (ND96 with 1.8 mM CaCl₂). Individual oocytes were defolliculated manually or *en masse* by 40-min incubation at room temperature in osmotic shock solution (130 mM K₂HPO₄, 1 mg/ml bovine serum albumin, pH 6.5 with HCl; Pajor, 1995) followed by several washes in recording solution. Within 1 day, they were injected with 5–50 nl of mRNA (10–200 pg/nl/subunit) mixed in a ratio of 1:1 (α : β , β : γ , or β : χ) or 1:1:10 (α : β : γ or α : β : χ). These ratios were determined to produce maximal assembly of γ - or χ -containing channels (Boileau AJ and Czajkowski C. Improved measurements of GABA-elicited currents and diazepam potentiation in recombinant GABA_A receptor channels expressed in *Xenopus* oocytes, manuscript in preparation). Oocytes were stored at 17–19° in recording solution supplemented with 100 μ g/ml gentamicin and 100 μ g/ml bovine serum albumin and were used for electrophysiological experiments 2–14 days after injection. The total amount of cRNA was scaled to yield maximal GABA-induced currents of ~3–8 μ A for α 1 β 2 γ 2S and α 1 β 2 χ . The β 2 γ 2S and β 2 χ subunit combinations yielded less current, usually 0.5–3 μ A. cRNA concentrations were calculated by UV absorption and corroborated by comparison with RNA standards on 1.5% agarose gels.

Voltage-clamp analysis. Oocytes under two-electrode voltage-clamp (*V_{hold}* = –80 mV) were perfused continuously with ND96/Ca²⁺ recording solution at a rate of 5 ml/min. In general, drugs and reagents were dissolved in ND96/Ca²⁺. The stock diazepam solution was made in dimethylsulfoxide. No differences in currents were observed with the vehicle. GABA responses were scaled for run-down or run-up by comparison with a low, nonsensitizing concentration of drug applied just before the drug concentration tested. Diazepam potentiation was recorded at ~EC₇ to EC₂₀ for GABA (1 μ M GABA for α 1 β 2 γ 2S and α 1 β 2 χ , 40 μ M GABA for β 2 γ 2S). Potentiation is defined as $[I_{(\text{GABA} + \text{DZ})} / I_{\text{GABA}}] - 1$, where *I_(GABA + DZ)* is the current response in the presence of diazepam, and *I_{GABA}* is the control GABA current. Standard two-electrode voltage-clamp recording was performed using a GeneClamp 500 (Axon Instruments, Burlingame, CA) interfaced to a computer with an IT-16 A/D device (Instrutech,

Great Neck, NY). Electrodes were filled with 3 M KCl and had a resistance of 0.5–1.5 MΩ.

Data acquisition and analysis were performed using AxoData, AxoGraph (Axon Instruments), and Prism (GraphPAD Software, San Diego, CA). All statistical comparisons used Student's *t* test for independent samples (Snedecor and Cochran, 1980).

Results

BZD and GABA Binding to αβγ Receptors

To create chimeric subunits containing amino-terminal domains of the γ2S subunit and carboxyl-terminal domains of the α1 subunit, we modified a published method (Moore and Blakely, 1994) to specifically target crossovers to occur in the extracellular amino-terminal domain before M1 (see Materials and Methods; Fig. 1A). Chimeras (χ) used here, named for the γ2S amino acid at which the crossovers occur, are χ40, χ82, χ107, χ113, χ161, and χ167 (Fig. 1B).

To determine whether the chimeric subunits contained appropriate γ2S domains for BZD binding, they were individually expressed with wild-type α1 and β2 subunits in HEK 293 cells to form α1β2χ receptors, and the binding of 100 nM [³H]flunitrazepam was measured. Only two chimeras, χ161 and χ167, which contain the amino-terminal 161 or 167 amino acid residues of the γ2S subunit, exhibited significant levels of specific [³H]flunitrazepam binding (Fig. 2). No significant specific [³H]flunitrazepam binding was detected after expression of single subunits of wild-type or chimeric origin; two-subunit combinations using α1β2, α1γ2S, β2γ2S, or β2χ; or α1β2χ combinations with χ40, χ82, χ107, or χ113.

The affinity of α1β2γ2S, α1β2χ161, and α1β2χ167 receptors for [³H]flunitrazepam (BZD agonist), Ro15–1788 (BZD antagonist), and Ro15–4513 (BZD inverse agonist) was measured by radioligand saturation and competition experiments to determine whether χ161- and χ167-containing receptors were altered in their ability to bind different classes of BZDs. Results from saturation binding experiments demonstrated that α1β2χ161 and α1β2χ167 receptors had *B*_{max} values and equilibrium dissociation constants (*K*_D) for [³H]flunitrazepam similar to those of α1β2γ2S receptors, with *K*_D values of 13.3, 11.3, and 9.9 nM, respectively (Fig. 3,




Fig. 2. αβχ161 and αβχ167 receptors bind [³H]flunitrazepam. Chimeric subunits were individually expressed with wild-type α1 and β2 subunits in HEK 293 cells, and the binding of 100 nM [³H]flunitrazepam was measured (see Materials and Methods). Note that only two chimeras, χ161 and χ167, which contain the amino-terminal 161 and 167 amino acid residues of the γ2 sequence respectively, specifically bound [³H]flunitrazepam. Percentages were calculated by normalizing specific [³H]flunitrazepam binding of α1β2γ2S, α1β2, or α1β2χ receptors to α1β2γ2S binding. Results are mean ± standard error. The number of individual experiments are shown in parentheses.




Fig. 3. Saturation binding of [³H]flunitrazepam to membranes prepared from HEK 293 cells expressing α1β2γ2 and α1β2χ161 receptors. *K*_D and *B*_{max} values for [³H]flunitrazepam were calculated by nonlinear least-squares fit of specifically bound [³H]flunitrazepam (see Materials and Methods). Data shown are from a single experiment repeated multiple times with similar results; points, mean ± standard error of triplicate determinations. Results are summarized in Table 1.

Table 1). Competition binding experiments using Ro15–1788 or Ro15–4513 showed no significant differences from α1β2γ2S in the *K*_I values for these compounds (Table 1).

The dissociation constants for [³H]muscimol binding (a GABA binding site agonist) to α1β2, α1β2γ2S, and α1β2χ161 receptors also were determined. The affinity and *B*_{max} values for [³H]muscimol binding to χ161-containing receptors were similar to α1β2γ2S receptors (α1β2χ161: *K*_D = 88.3 ± 5.9 nM, *B*_{max} = 1.32 ± 0.19 pmol/mg, 3 experiments; α1β2γ2S: *K*_D = 70.0 ± 8.0 nM, *B*_{max} = 1.21 ± 0.18 pmol/mg, 20 experiments). α1β2 receptors bound [³H]muscimol with a ~2-fold higher affinity (*K*_D = 46.2 ± 9.0 nM, *B*_{max} = 1.23 ± 0.14 pmol/mg, 5 experiments).¹ The small but significant difference in [³H]muscimol affinity in α1β2γ2S and α1β2χ161 receptors versus α1β2 receptors (*p* < 0.01) may be diagnostic for the presence of γ2 domains in the pentameric receptor complex.

Allosteric Coupling of the GABA and BZD Binding Sites

Two-electrode voltage-clamp studies. Because robust BZD binding does not necessarily indicate functional coupling of the BZD and GABA binding sites, the chimeras were tested with two-electrode voltage-clamp for the ability of diazepam to potentiate the GABA-mediated Cl[−] current. χ40, χ82, χ107, and χ113 showed no diazepam potentiation of

¹ The affinities for [³H]muscimol binding measured are 2–5-fold lower than values reported by others in the field due to different assay conditions. In our binding assays, incubations with radioligand are carried out at room temperature (as opposed to on ice or 4°) to more closely mimic our electrophysiological recording conditions.

TABLE 1

Binding affinities for three different types of BZDs using wild-type and chimeric receptors

The affinity of $\alpha 1\beta 2\gamma 2S$, $\alpha 1\beta 2\chi 161$, and $\alpha 1\beta 2\chi 167$ receptors for [³H]flunitrazepam (BZD agonist), Ro15-1788 (BZD antagonist), and Ro15-4513 (BZD inverse agonist) was measured by radioligand saturation and competition binding experiments. $\alpha 1\beta 2\chi 161$ and $\alpha 1\beta 2\chi 167$ receptors had an affinity similar to that of $\alpha 1\beta 2\gamma 2S$ for all three types of BZD-site ligands tested. Results shown are mean \pm standard error; n is the number of independent experiments.

	Flunitrazepam			Ro15-1788		Ro15-4513	
	K_D	B_{max}	n	K_I	n	K_I	n
	nM	pmol/mg		nM		nM	
$\alpha 1\beta 2\gamma 2S$	9.9 ± 0.8	0.65 ± 0.07	16	4.3 ± 0.9	9	17.9 ± 4.9	9
$\alpha 1\beta 2\chi 161$	11.3 ± 1.7	0.34 ± 0.03	4	6.9 ± 1.2	5	25.5 ± 4.0	4
$\alpha 1\beta 2\chi 167$	13.3 ± 3.5	0.57 ± 0.17	3	6.4 ± 1.7	3	41.0 ± 11.2	3

the GABA response when coexpressed with wild-type $\alpha 1$ and $\beta 2$ cRNA in *X. laevis* oocytes, whereas $\chi 161$ and $\chi 167$ exhibited small but detectable amounts of potentiation. The traces in Fig. 4A show diazepam potentiation of GABA-activated currents from oocytes expressing $\alpha 1\beta 2\gamma 2S$, $\alpha 1\beta 2\chi 161$, and

$\alpha 1\beta 2\chi 167$ GABA_A receptors. Fig. 4B plots the potentiation of GABA-activated currents for $\alpha 1\beta 2\gamma 2S$, $\alpha 1\beta 2\chi 161$, $\alpha 1\beta 2\chi 167$, and $\alpha 1\beta 2$ receptors as a function of diazepam concentration. The maximal diazepam potentiation of $\alpha 1\beta 2\chi 161$ and $\alpha 1\beta 2\chi 167$ receptors was dramatically lower (~ 7 -fold) than that for wild-type $\alpha 1\beta 2\gamma 2S$ receptors (Table 2). This result was surprising, considering that $\alpha 1\beta 2\chi 161$ and $\alpha 1\beta 2\chi 167$ receptors bound BZDs with wild-type affinity (Table 1), and indicates an uncoupling of high affinity BZD binding from BZD potentiation. Although the potentiation of $\alpha 1\beta 2\chi 161$ and $\alpha 1\beta 2\chi 167$ receptors was small, it was significant ($p < 0.05$) at diazepam concentrations above 100 nM compared with $\alpha 1\beta 2$, $\alpha 1\beta 2\chi 40$, or $\alpha 1\beta 2\chi 113$ (Table 2). On normalization of the data to maximal potentiation, a ~ 6 -fold increase in the EC_{50} for diazepam potentiation was observed in $\chi 161$ - and $\chi 167$ -containing receptors compared with wild-type receptors (Fig. 4B, inset; Table 2).

Because a change in GABA EC_{50} value could potentially explain the decrease in BZD potentiation observed, GABA dose responses were measured. Current amplitudes at 1 μM (test concentration) and 10 mM GABA (maximal concentration) for all six $\alpha 1\beta 2\chi$ combinations (data not shown) and GABA dose-response curves for $\alpha 1\beta 2\chi 161$ and $\alpha 1\beta 2\chi 167$ were similar to those for wild-type $\alpha 1\beta 2\gamma 2S$ receptors (Fig. 5, Table 2). These data indicate that the decrease in diazepam potentiation measured for $\alpha 1\beta 2\chi 161$ and $\alpha 1\beta 2\chi 167$ receptors was not caused by an alteration in GABA-mediated activation. Interestingly, the GABA EC_{50} values for $\alpha 1\beta 2\gamma 2S$, $\alpha 1\beta 2\chi 161$, and $\alpha 1\beta 2\chi 167$ receptors were statistically different than that for $\alpha 1\beta 2$ receptors ($p < 0.001$, Table 2). The small change in GABA potency in the triple subunit combinations compared with $\alpha 1\beta 2$ receptors may be indicative of the presence of the $\gamma 2S$ subunit or domains (see Discussion) and suggests that after injection of $\alpha 1\beta 2\chi$ subunit combinations into *X. laevis* oocytes, a majority of the expressed receptors contain a chimeric subunit.

Equilibrium binding studies. To gain further insight into whether the decrease in the allosteric coupling of the GABA and BZD binding sites was due to an intrinsic property of the chimera-containing receptors, the ability of GABA to potentiate [³H]flunitrazepam binding to membrane homogenates prepared from HEK 293 cells expressing $\alpha 1\beta 2\gamma 2S$, $\alpha 1\beta 2\chi 161$, and $\alpha 1\beta 2\chi 167$ receptors was measured. In this experimental paradigm, only the receptor populations containing a $\gamma 2S$ or chimeric subunit were monitored because $\alpha 1\beta 2$ receptors do not bind BZDs. Fig. 6 plots the potentiation of specific [³H]flunitrazepam binding of $\alpha 1\beta 2\gamma 2S$ and $\alpha 1\beta 2\chi 161$ receptors as a function of GABA concentration. The GABA-mediated potentiation of [³H]flunitrazepam binding in $\alpha 1\beta 2\chi 161$ receptors was nearly abolished at concen-




Fig. 4. Diazepam potentiates $\alpha 1\beta 2\chi 161$ and $\alpha 1\beta 2\chi 167$ receptors. **A**, Trace recordings from cells injected with chimeric construct $\alpha 1\beta 2\gamma 2S$ (left), $\alpha 1\beta 2\chi 161$ (middle), and $\alpha 1\beta 2\chi 167$ (right). Cells were voltage-clamped at -80 mV and perfused with ND96 recording solution or ND96 with 1 μM GABA or 1 μM GABA plus diazepam (transition to diazepam-containing solutions: white arrowheads). Far left, diazepam concentrations. Cells were washed with ND96 recording solution for 5–20 min between drug applications. Note that wild-type $\alpha 1\beta 2\gamma 2S$ subunits show a large potentiation, whereas chimeras show smaller potentiation even at a high concentration of diazepam (1 μM). **B**, Oocytes injected with wild-type $\alpha 1\beta 2\gamma 2S$ (1:1:10), $\alpha 1\beta 2$ (1:1), and $\alpha 1\beta 2\chi$ (1:1:10) cRNA mixtures were treated with a range of diazepam concentrations in the presence of GABA and further analyzed. A potentiation response ratio was determined by dividing the peak current for $\alpha 1\beta 2\gamma 2S$ (■), $\alpha 1\beta 2$ (●), $\alpha 1\beta 2\chi 161$ (□), and $\alpha 1\beta 2\chi 167$ (○) exposed to 1 μM GABA plus diazepam (DZ) by the response to 1 μM GABA alone. Data were fitted to a curve described by the equation $Y = \text{Min} + (\text{Max} - \text{Min}) / (1 + 10^{[(\log EC_{50} - X) \cdot n]})$, where Max is the maximal potentiation, Min is the potentiation at the lowest drug concentration tested, X is the logarithm of diazepam concentration, EC_{50} is the half-maximal potentiation response, and n is the Hill coefficient. Data points represent mean potentiation from four or more cells from two or more batches of oocytes. Error bars, standard deviation. The parameters from the curve fits are presented in Table 2. **Inset**, a plot of the same data after normalizing to the maximum response for $\alpha 1\beta 2\gamma 2S$ (■), $\alpha 1\beta 2\chi 161$ (□), and $\alpha 1\beta 2\chi 167$ (○) receptors displays the shift in EC_{50} value for chimera-containing receptors.

TABLE 2
Summary of voltage-clamp results

Dose-response data for wild-type and chimeric subunit combinations for GABA and diazepam potentiation of GABA-mediated Cl^- current in *X. laevis* oocytes are tabulated. Two-electrode voltage-clamp and data analysis was performed as described (see Materials and Methods). Mean and standard deviation values for maximum potentiation, EC_{50} values, and Hill coefficients (n_H) were calculated from dose-response data (Figs. 4b and 5) with the use of Prism software.

	GABA		Diazepam potentiation		
	EC_{50} μM	n_H	Maximum potentiation	EC_{50}	n_H
	μM			nM	
$\alpha 1\beta 2\gamma 2$	12.7 ± 0.7	1.07 ± 0.05	1.91 ± 0.17	51 ± 6	1.11 ± 0.10
$\alpha 1\beta 2$	8.2 ± 0.4	0.93 ± 0.04			
$\beta 2\gamma 2$	210 ± 12	0.75 ± 0.03	1.03 ± 0.07	24 ± 2	0.89 ± 0.06
$\alpha 1\beta 2\chi 161$	17.4 ± 1.4	0.93 ± 0.06	0.26 ± 0.01	295 ± 34	1.41 ± 0.12
$\alpha 1\beta 2\chi 167$	14.9 ± 1.3	0.96 ± 0.06	0.28 ± 0.02	324 ± 53	1.30 ± 0.17




Fig. 5. GABA dose response for chimeras is similar to that of wild-type $\alpha 1\beta 2\gamma 2$ receptors. Oocytes were injected with $\alpha 1\beta 2\gamma 2$ (1:1:10, \blacksquare), $\alpha 1\beta 2$ (1:1, \bullet), $\beta 2\gamma 2$ (1:1, \blacktriangle), and $\alpha 1\beta 2\chi 161$ (1:1:10, \square) cRNA to determine whether reduced diazepam potentiation of chimeras was due to any shift in GABA dose-response curves. Data were fitted to a curve described by the equation $Y = \text{Min} + (\text{Max} - \text{Min}) / (1 + 10^{(\log \text{EC}_{50} - X) \cdot n})$, where Max is the maximal response, Min is the response at the lowest drug concentration tested, X is the logarithm of GABA concentration, EC_{50} is the half-maximal response, and n is the Hill coefficient. Dose response for both $\alpha 1\beta 2\chi 161$ and $\alpha 1\beta 2\chi 167$ (not shown, for clarity) are most similar to that of wild-type $\alpha 1\beta 2\gamma 2$. Data points, mean peak current from four or more cells from two or more batches of oocytes; error bars, standard deviation. Parameters determined from the curve fits are presented in Table 2.

trations of GABA up to 100 μM . Similar results were seen for $\alpha 1\beta 2\chi 167$ receptors. In contrast, GABA potentiated [^3H]flunitrazepam binding of $\alpha 1\beta 2\gamma 2\text{S}$ receptors with an EC_{50} value of 1.20 ± 0.15 μM and a maximal potentiation of 1.25 ± 0.05 (Fig. 6). These results suggest that the BZD and GABA binding sites are uncoupled in $\alpha 1\beta 2\chi 161$ and $\alpha 1\beta 2\chi 167$ receptors and that the uncoupling is due to a property of the chimera-containing receptors. In addition, these results corroborate the markedly reduced diazepam potentiation observed electrophysiologically.

Further Localization of the BZD Binding Site

By comparing the γ/α crossover positions (Fig. 1B) in chimeras that bound BZDs with high affinity ($\chi 161$, $\chi 167$) with those that did not ($\chi 40$, $\chi 82$, $\chi 107$, and $\chi 113$), a region of 48 amino acid residues (R114-D161) of the $\gamma 2\text{S}$ subunit that is essential for BZD binding can be identified. This determination requires that $\alpha 1\beta 2\chi$ receptor combinations using $\chi 40$, $\chi 82$, $\chi 107$, or $\chi 113$ subunits were assembled and expressed efficiently. To address this question, the chimeric subunits were individually expressed with $\beta 2$ subunits in *X. laevis* oocytes and the ability of GABA to activate a Cl^- -specific




Fig. 6. GABA potentiation of [^3H]flunitrazepam binding on wild-type and chimeric receptors. GABA potentiation of 2.5 nM [^3H]flunitrazepam binding was measured in membrane homogenates prepared from HEK 293 cells expressing $\alpha 1\beta 2\gamma 2$ (\blacksquare) and $\alpha 1\beta 2\chi 161$ (\square) receptors (see Materials and Methods). Potentiation was calculated by dividing specific dpm in the presence of GABA by specific dpm in the absence of GABA, and the resulting data were fit to a single-site sigmoidal dose-response curve (see Materials and Methods; Fig. 4). Data points, mean potentiation of binding from eight experiments with $\alpha 1\beta 2\gamma 2$ and six experiments with $\alpha 1\beta 2\chi 161$. Error bars, standard error.

current was tested. Because the dual subunit combinations $\alpha 1\beta 2$ and $\beta 2\gamma 2\text{S}$ form functional GABA-gated receptors when expressed in *X. laevis* oocytes (Table 2; Sigel et al., 1990) and $\beta 2$ subunits expressed alone cannot, expression of $\beta 2\chi$ combinations directly tests the capability of the chimeras to assemble into functional receptors. We observed GABA-mediated Cl^- currents using all six $\beta 2\chi$ subunit combinations (data not shown). $\beta 2\chi 40$, $\beta 2\chi 82$, $\beta 2\chi 161$, and $\beta 2\chi 167$ had maximal GABA current amplitudes similar to $\beta 2\gamma 2\text{S}$ ($3 \geq \mu\text{A}$). The maximal GABA currents of $\beta 2\chi 107$ and $\beta 2\chi 113$ receptors were ~ 5 -fold smaller. Interestingly, although diazepam potentiated the GABA response in $\beta 2\gamma 2\text{S}$ receptors ($\text{EC}_{50} = 24 \pm 2$ nM), diazepam did not potentiate the GABA current of any of the $\beta 2\chi$ receptors (see Discussion). Nevertheless, these results demonstrate that the chimeric subunits can be assembled into functional $\beta 2\chi$ receptors. If the chimeric subunits assemble into functional $\alpha 1\beta 2\chi$ receptors in a similar manner, a region of 48 amino acids delimited by $\chi 113$ to $\chi 161$ in $\gamma 2\text{S}$ is required for BZD binding.

To determine whether this region is not only necessary but also sufficient for BZD binding, a chimeric subunit ($\chi 114$ – 161 , Fig. 1B) was constructed that replaced the region from H101 to D148 in the $\alpha 1$ subunit with the homologous $\gamma 2\text{S}$ region (R114-D161). This chimera, when expressed with wild-type $\alpha 1$ and $\beta 2$ subunits, did not specifically bind

[³H]flunitrazepam, [³H]Ro15-1788, or [³H]Ro15-4513 at concentrations up to 200 nM (data not shown). To determine whether χ 114-161 could assemble into a functional receptor, it was expressed with wild-type β 2 subunits, and the binding of [³H]muscimol was measured. The χ 114-161 β 2 receptor specifically bound [³H]muscimol with a K_D value of 108 ± 30 nM and a B_{\max} value of 0.6 ± 0.4 pmol/mg (four experiments). Membrane homogenates prepared from HEK 293 cells expressing β 2 alone did not specifically bind [³H]muscimol. These data suggest that the lack of BZD binding by α 1 β 2 χ 114-161 receptors cannot be explained by an impairment in the assembly or expression of the χ 114-161 subunit. Therefore, although the R114-D161 region of γ 2S may be necessary for BZD binding, it clearly is not sufficient.

Because χ 114-161 did not bind BZDs, two $\gamma/\alpha/\gamma/\alpha$ chimeras were constructed (χ 40/114-161 and χ 82/114-161; Fig. 1B) that replaced in both χ 40 and χ 82 the α 1 region from H101 to D148 with the homologous γ 2S region (R114-D161). These chimeras were expressed with wild-type α 1 and β 2 subunits in HEK 293 cells and the binding of [³H]flunitrazepam was measured. The α 1 β 2 χ 40/114-161 receptors did not specifically bind [³H]flunitrazepam or [³H]Ro15-4513, whereas α 1 β 2 χ 82/114-161 receptors bound [³H]flunitrazepam in a similar fashion to α 1 β 2 γ 2S receptors with a K_D of 17.8 ± 5.4 nM and a B_{\max} of 0.36 ± 0.06 pmol/mg (six experiments) (Fig. 7). α 1 β 2 χ 82/114-161 receptors showed no significant differences from α 1 β 2 γ 2S receptors in the K_I values for Ro15-1788 ($K_I = 12.7 \pm 3.1$ nM, three experiments) or Ro15-4513 ($K_I = 23.0 \pm 9.4$ nM, four experiments). Thus, only two regions of the γ 2S subunit, Q1-W82 and R114-D161, are required for high affinity BZD binding. Amino acid sequence comparison of α 1 β 2 χ 40/114-161 receptors, which do not bind BZDs, and α 1 β 2 χ 82/114-161 receptors suggests that high affinity BZD binding requires only the γ 2S domains K41-W82 and R114-D161.

Discussion

TRCP. The use of TRCP was successful. By choosing available restriction sites, we specifically targeted DNA sequence crossovers to the amino-terminal regions of the α 1 and γ 2S subunits (see Materials and Methods). Moreover, by engineering a sequence with silent mutations to provide new




Fig. 7. α 1 β 2 χ 82/114-161 receptors bind [³H]flunitrazepam. Chimeric subunits were individually expressed with wild-type α 1 and β 2 subunits in HEK 293 cells and the binding of 100 nM [³H]flunitrazepam was measured (see Materials and Methods). Percentages were calculated by normalizing specific [³H]flunitrazepam binding of α 1 β 2 χ receptors to α 1 β 2 γ 2S binding. Results are presented as mean \pm standard error. The number of individual experiments is shown in parentheses. ▨, α 1 β 2 γ 2S receptors; ■, α 1 β 2 χ 40/114-161 receptors; □, α 1 β 2 χ 82/114-161 receptors.

restriction enzyme sites, one could choose any region to target for crossover events. Thus, TRCP should prove useful for any multisubunit protein.

Despite relatively low amino acid identity (Shivers *et al.*, 1989), the intersubunit chimeras described in this study (γ 2S/ α 1) formed functional channels. Intersubunit chimeras can furnish different structural/functional information from that furnished by subunit subtype chimeras (e.g., α 1/ α 3), such as determining areas that are unique to each subunit and regions that are interchangeable between subunits. This was particularly useful because we were interested in identifying structural determinants of BZD binding and potentiation that were unique to the γ subunit.

Identification of γ 2S BZD binding region. The results demonstrate that a chimeric subunit with γ 2S sequence in the first 161 amino acid residues and α 1 sequence in the remainder can efficiently substitute for a wild-type γ 2S subunit in assembling functional cell surface GABA_A receptors that bind BZDs with high affinity. This proves that the γ 2S determinants for binding BZD agonists (diazepam and flunitrazepam), inverse agonists (Ro15-4513), and antagonists (Ro15-1788) lie in the major extracellular portion of the subunit from the amino terminus through the cysteine-cysteine loop. Because electrophysiological experiments with β 2 χ combinations indicate that all of the chimeric subunits are expressible, we assume the chimeras also are expressed in α 1 β 2 χ receptors. Amino acid sequence comparison of α 1 β 2 χ 113 receptors, which do not exhibit BZD binding, with α 1 β 2 χ 161 receptors leads to the conclusion that high affinity BZD binding requires γ 2S domain or domains between amino acid residues 113 and 161. However, a chimera that contains only these γ 2S residues (the $\alpha/\gamma/\alpha$ chimera, χ 114-161), does not exhibit BZD binding, demonstrating that this 48-amino acid span is not sufficient for high affinity BZD binding. In other words, elements of γ 2S upstream from position 114 must be involved in the formation of the binding pocket.

A chimera that contains the amino-terminal 82 amino acid residues from γ 2S in addition to residues 114-161 (the $\gamma/\alpha/\gamma/\alpha$ chimera, χ 82/114-161) bound BZDs when expressed with α 1 and β 2 subunits. This result demonstrates that the γ 2 subunit determinants for expression of high affinity BZD binding are contained within two domains of the γ 2 subunit, Q1-W82 and R114-D161. Furthermore, if χ 40/114-161, which does not bind BZDs, is expressed, the results indicate that BZD binding requires the γ 2S domains K41-W82 and R114-D161. Although direct evidence that χ 40/114-161 is expressed is not shown, it is reasonable to assume that it is because both χ 40 and χ 114-161 are expressed.

It has been postulated that the BZD and GABA binding sites are conserved structures, with a BZD binding site at a γ/α subunit interface and a GABA binding site at an α/β interface. Many of the γ/α interface residues that have been identified as being important for BZD binding (γ 2F77, α 1Y159, α 1T206, and α 1Y209) are homologous to the α/β interface residues that are important for binding GABA (α 1F64, β 2Y157, β 2T202, and β 2Y205). In the aligned sequences of the subunits, these residues are conserved. However, because the molecular structures of GABA and BZDs are quite distinct, it seems likely that other nonconserved residues will be required to impart pharmacological specificity to these sites.

Our results confirm the potential roles for γ 2F77 and/or

$\gamma 2$ T142 in BZD effects. These residues, which have previously been implicated in BZD effects (Mihic *et al.*, 1994; Buhr *et al.*, 1996, 1997), occur within the two $\gamma 2$ regions identified in this study. However, although these residues may be important for BZD binding, both are conserved between the $\alpha 1$ and $\gamma 2$ subunits. Thus, other $\gamma 2$ residues are needed to impart a unique $\gamma 2$ flavor and pharmacologically distinguish the BZD binding site pocket from the GABA binding site pocket. In this study, we have localized the specific $\gamma 2$ determinants for BZD binding to K41-W82 and R114-D161.

A recent study (Buhr and Sigel, 1997) using $\gamma 3/\gamma 2$ chimeras has identified one amino acid residue ($\gamma 2$ M130) and perhaps a second ($\gamma 2$ M57) that seem to be important for controlling the affinity of zolpidem, an imidazopyridine. These residues occur within the two $\gamma 2$ regions identified in this study. Mutations of these residues, however, have little or no effect on binding of classic BZDs. Thus, although subunit subtype chimeras are useful in examining the subtle pharmacological differences between γ subunits, these types of chimeras are not as helpful for identifying residues that are absolutely necessary for BZD binding. In our study, the novel use of $\gamma 2/\alpha 1$ intersubunit chimeras allowed us to identify two distinct regions unique to the γ subunit that are required for the high affinity binding of a variety of different types of BZD ligands.

Galzi and Changeux (1994) proposed a four-loop model for ligand binding. Perhaps the three potential BZD binding regions of $\alpha 1$ (H101, Y159-T162, and G200-V211) correspond to three of these loops. If the model holds true, our results suggest that the fourth loop, presumed to be a part of an adjacent subunit, is contributed by residues in two regions of the $\gamma 2$ subunit (K41-W82 and R114-D161). Moreover, if the GABA-binding region of α is homologous to the BZD-binding region of γ , then our finding that more than one region in the γ subunit is needed for BZD binding suggests that there may be other regions in the α subunit in addition to F64 that are involved in the formation of a GABA-binding site.

Chimeric uncoupling of BZD binding and potentiation. Despite high affinity BZD binding with $\alpha 1\beta 2\chi 161$ or $\alpha 1\beta 2\chi 167$, there are significant differences in the behavior of the resultant channels with regard to BZD allosteric coupling. By using two different assays (electrophysiological and equilibrium radioligand binding) and two different expression systems (*X. laevis* oocytes and HEK 293 cells), we have shown that the allosteric interactions between the GABA and BZD binding sites of $\alpha 1\beta 2\chi 161$ and $\alpha 1\beta 2\chi 167$ receptors are markedly decreased compared with wild-type $\alpha 1\beta 2\gamma 2$ S receptors (Figs. 4 and 6). Neither the decrease in diazepam potentiation of the GABA response nor the near abolishment in GABA potentiation of BZD binding is caused by a reduction in GABA sensitivity (Table 2) or muscimol binding affinity for $\alpha 1\beta 2\chi 161$ or $\alpha 1\beta 2\chi 167$ receptors. In addition, several pieces of evidence indicate that it is unlikely that the reduced potentiation is due to impaired assembly or expression of the $\chi 161$ and $\chi 167$ subunits: (1) B_{\max} for BZD binding of $\alpha 1\beta 2\chi 161$ and $\alpha 1\beta 2\chi 167$ receptors expressed in HEK 293 cells (Table 1) is similar to $\alpha 1\beta 2\gamma 2$ S receptors and suggests that these chimera-containing receptors are efficiently expressed, (2) $\alpha 1\beta 2\chi 161$ and $\alpha 1\beta 2\chi 167$ GABA EC_{50} and K_D values for muscimol binding are more similar to those of $\alpha 1\beta 2\gamma 2$ S than to those of $\alpha 1\beta 2$ receptors (Fig. 5, Table 2), suggesting full expression of a $\gamma 2$ element, and (3) $\beta 2\chi 161$

and $\beta 2\chi 167$ receptors expressed in *X. laevis* oocytes have maximal GABA-activated currents, similar to those of $\beta 2\gamma 2$ S receptors.

Taken together, these results indicate that the decreased coupling of BZD binding and potentiation is an intrinsic property of the $\chi 161$ - and $\chi 167$ -containing receptors and demonstrate that transduction of high affinity BZD binding (binding indistinguishable from wild-type) to full agonist potentiation must require additional and/or different $\gamma 2$ subunit regions than those contained in the amino-terminal 167 amino acids of the $\gamma 2$ S subunit. Furthermore, these results suggest that a γ element is responsible for the ability of GABA to potentiate BZD binding. Experiments are under way to delineate residues, downstream from $\chi 167$, that are determinant for the allosteric interactions. In addition, these findings underscore the fact that a measured alteration in allosteric coupling does not necessarily imply any change in ligand binding.

Also of interest is the lack of measurable diazepam potentiation of the GABA response with any $\beta 2\chi$ subunit combination expressed in *X. laevis* oocytes. $\beta 2\gamma 2$ S receptors display both GABA activation and BZD potentiation of the Cl^- current (Table 2), yet $\beta 2\chi 161$ and $\beta 2\chi 167$ receptors seem to be devoid of diazepam response despite the fact that when they are coexpressed with $\alpha 1$, they exhibit BZD binding (Table 1) and diazepam potentiation (Fig. 4). We postulate that the rightward shift in the GABA dose-response curve for $\beta 2\gamma 2$ S receptors (Fig. 5; Sigel *et al.*, 1990) represents a diminished capacity for $\gamma 2$ GABA-binding regions to substitute for homologous $\alpha 1$ regions in the formation of a GABA-binding pocket at the interface with a β subunit. Recent work indicates a similar inability of $\gamma 2$ to substitute for $\alpha 1$ in BZD actions (Amin *et al.*, 1997), even though $\beta 2\gamma 2$ S receptors display BZD sensitivity akin to that of $\alpha 1\beta 2\gamma 2$ S receptors (Table 2; Sigel *et al.*, 1990; Im *et al.*, 1993). If inefficient allosteric coupling in the chimeras is superimposed on an already low GABA binding affinity contributed by the $\gamma 2$ regions, this might make potentiation of the $\beta 2\chi$ receptors difficult to measure. Alternatively, residues carboxyl-terminal to $\gamma 2$ L167 might be needed for formation of fully functional GABA or BZD binding pockets in $\beta 2\chi$ receptors. Finally, it is possible that our chimeras will not bind BZDs in the absence of an α subunit. Whether $\beta 2\chi$ receptors have altered BZD binding or altered allosteric coupling of the GABA and BZD binding pockets requires further investigation.

Previous studies have shown that chronic exposure to GABA_A receptor modulators, including BZDs, can cause a decrease in coupling between binding sites, as measured by potentiation of [³H]flunitrazepam binding (Hu and Ticku, 1994; Friedman *et al.*, 1996). This observation has been postulated to represent one mechanism underlying drug tolerance. In $\alpha 1\beta 2\chi 161$ and $\alpha 1\beta 2\chi 167$ receptors, the GABA and BZD binding sites are already uncoupled; therefore, these chimeras can be used to glean structural information about regions of the $\gamma 2$ S and $\alpha 1$ subunits involved in allosteric interactions. Mutation of these chimeric subunits such that coupling is enhanced will lead to a better understanding of allosteric cross-talk between binding sites and may help identify the structural elements underlying allosteric modulation. Studies using whole-cell and outside-out patch-clamp on chimeras expressed in HEK 293 cells also will be of inter-

est, to determine the kinetics underlying these alterations in coupling. The chimeric subunits described in this report may be especially informative in this regard.

In summary, we demonstrated that γ/α chimeras can be expressed and form functional GABA_A receptors in the presence of wild-type subunits. We identified two domains of the $\gamma 2$ subunit, K41-W82 and R114-D161, that together are required for high affinity BZD binding. In these regions, several amino acid residues are not conserved between the $\alpha 1$ and $\gamma 2$ subunits and are likely candidates for BZD binding site residues. Notably, diazepam potentiation of the GABA response and GABA potentiation of BZD binding are reduced in chimeras containing these regions due to impaired allosteric coupling. Thus, by using intersubunit chimeras, the molecular dissection of multiple domains associated with ligand-binding sites has been described and distinguished from areas that function in allosteric coupling.

Acknowledgments

We thank Polo Chen for technical assistance, Dr. Nicholas Cozzi for help in developing the transient transfection and radioligand binding protocols used in this study, Dr. David Wagner for critical reading of the manuscript, and Drs. Eugenia Jones, Robert Pearce, and Gail Robertson for helpful discussions.

References

- Amin J, Brookskay A, and Weiss DS (1997) Two tyrosine residues on the α subunit are crucial for benzodiazepine binding and allosteric modulation of γ -aminobutyric acid_A receptors. *Mol Pharmacol* **51**:833–841.
- Boileau AJ, Cozzi NV, Chen P, and Czajkowski C (1996) Identification of GABA and diazepam-responsive regions of the GABA_A receptor using $\gamma 2/\alpha 1$ subunit chimeras. *Soc Neurosci Abstr* **22**(Part 2):1284.
- Buhr A, Baur R, Malherbe P, and Sigel E (1996) Point mutations of the $\alpha 1\beta 2\gamma 2$ γ -aminobutyric acid_A receptor affecting modulation of the channel by ligands of the benzodiazepine binding site. *Mol Pharmacol* **49**:1080–1084.
- Buhr A, Baur R, and Sigel E (1997) Subtle changes in residue 77 of the γ subunit of $\alpha 1\beta 2\gamma 2$ GABA_A receptors drastically alter the affinity for ligands of the benzodiazepine binding site. *J Biol Chem* **272**:11799–11804.
- Buhr A and Sigel E (1997) A point mutation in the γ subunit of γ -aminobutyric acid type A receptors results in altered benzodiazepine binding site specificity. *Proc Natl Acad Sci USA* **94**:8824–8829.
- Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I₅₀) of an enzymatic reaction. *Biochem Pharmacol* **22**:3099–3108.
- Chou T (1974) Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. *Mol Pharmacol* **10**:235–247.
- Czajkowski C, Gibbs TT, and Farb DH (1989) Transmembrane topology of the γ -aminobutyric acid_A/benzodiazepine receptor: subcellular distribution and allosteric coupling determined *in situ*. *Mol Pharmacol* **35**:75–84.
- Duncalfe LL, Carpenter MR, Smillie LB, Martin IL, and Dunn SM (1996) The major site of photoaffinity labeling of the γ -aminobutyric acid type A receptor by [³H]flunitrazepam is histidine 102 of the α subunit. *J Biol Chem* **271**:9209–9214.
- Friedman LK, Gibbs TT, and Farb DH (1996) γ -Aminobutyric acid_A receptor regulation: heterologous uncoupling of modulatory site interactions induced by chronic steroid, barbiturate, benzodiazepine, or GABA treatment in culture. *Brain Res* **707**:100–109.
- Galzi J-L and Changeux J-P (1994) Neurotransmitter-gated ion channels as unconventional allosteric proteins. *Curr Opin Struct Biol* **4**:554–565.
- Graham FL and van der Eb AJ (1973) Transformation of rat cells by DNA of human adenovirus 5. *Virology* **54**:536–539.
- Hu XJ and Ticku MK (1994) Chronic benzodiazepine agonist treatment produces functional uncoupling of the γ -aminobutyric acid-benzodiazepine receptor ionophore complex in cortical neurons. *Mol Pharmacol* **45**:618–625.
- Im HK, Im WB, Hamilton BJ, Carter DB, and Vonvoigtlander PF (1993) Potentiation of γ -aminobutyric acid-induced chloride currents by various benzodiazepine site agonists with the $\alpha 1\gamma 2$, $\beta 2\gamma 2$, and $\alpha 1\beta 2\gamma 2$ subtypes of cloned γ -aminobutyric acid type A receptors. *Mol Pharmacol* **44**:866–870.
- Karlin A and Akabas MH (1995) Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. *Neuron* **15**:1231–1244.
- Kleingoor C, Wieland HA, Korpi ER, Seeburg PH, and Kettenmann H (1993) Current potentiation by diazepam but not GABA sensitivity is determined by a single histidine residue. *Neuroreport* **4**:187–190.
- Liman ER, Tytgat J, and Hess P (1992) Subunit stoichiometry of a mammalian K⁺ channel determined by construction of multimeric cDNAs. *Neuron* **9**:861–871.
- Mihic SJ, Whiting PJ, Klein RL, Wafford KA, and Harris RA (1994) A single amino acid of the human γ -aminobutyric acid type A receptor $\gamma 2$ subunit determines benzodiazepine efficacy. *J Biol Chem* **269**:32768–32773.
- Moore KR and Blakely RD (1994) Restriction site-independent formation of chimeras from homologous neurotransmitter-transporter cDNAs. *Biotechniques* **17**:130–137.
- Ortells MO and Lunt GG (1995) Evolutionary history of the ligand-gated ion-channel superfamily of receptors. *Trends Neurosci* **18**:121–127.
- Pajor AM (1995) Sequence and functional characterization of a renal sodium/dicarboxylate cotransporter. *J Biol Chem* **270**:5779–5785.
- Pritchett DB and Seeburg PH (1991) γ -Aminobutyric acid type A receptor point mutation increases the affinity of compounds for the benzodiazepine site. *Proc Natl Acad Sci USA* **88**:1421–1425.
- Pritchett DB, Sontheimer H, Shivers BD, Ymer S, Kettenmann H, Schofield PR, and Seeburg PH (1989) Importance of a novel GABA_A receptor subunit for benzodiazepine pharmacology. *Nature (Lond)* **338**:582–585.
- Robertson GA, Warmke JM, and Ganetzky B (1996) Potassium currents expressed from *Drosophila* and mouse eag cDNAs in *Xenopus* oocytes. *Neuropharmacology* **35**:841–850.
- Sambrook J, Fritsch EF, and Maniatis T (1989) *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- Shivers BD, Killisch I, Sprengel R, Sontheimer H, Kohler M, Schofield PR, and Seeburg PH (1989) Two novel GABA_A receptor subunits exist in distinct neuronal subpopulations. *Neuron* **3**:327–337.
- Sieghart W (1995) Structure and pharmacology of γ -aminobutyric acid_A receptor subtypes. *Pharmacol Rev* **47**:181–234.
- Sigel E, Baur R, Trube G, Mohler H, and Malherbe P (1990) The effect of subunit composition of rat brain GABA_A receptors on channel function. *Neuron* **5**:703–711.
- Smith GB and Olsen RW (1995) Functional domains of GABA_A receptors. *Trends Pharmacol Sci* **16**:162–168.
- Snedecor GW and Cochran WG (1980) *Statistical Methods*. pp 96–98, Iowa State University Press, Ames, IA.
- Stephenson FA (1995) The GABA_A receptors. *Biochem J* **310**:1–9.
- Wieland HA and Luddens H (1994) Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABA_A receptor into a diazepam-preferring GABA_A receptor. *J Med Chem* **37**:4576–4580.
- Wieland HA, Luddens H, and Seeburg PH (1992) A single histidine in GABA_A receptors is essential for benzodiazepine agonist binding. *J Biol Chem* **267**:1426–1429.

Send reprint requests to: Dr. Cynthia Czajkowski, Department of Neurophysiology, University of Wisconsin, 1300 University Avenue, Room 197A MSC, Madison, WI 53706. E-mail: czajkowski@neurophys.wisc.edu